A COST‐EFFECTIVENESS MODEL OF ALTERNATIVE STATINS TO ACHIEVE TARGET LDL‐CHOLESTEROL LEVELS

SUMMARY An economic model was developed to estimate the relative cost‐effectiveness of alternative HMG‐CoA reductase inhibitors (statins) – atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin – to achieve target low‐density lipoprotein cholesterol (LDL‐C) levels in a population of secondary CHD prevention patients. By using a cholesterol target as the endpoint of interest and a dose titration approach, the model assumes that the statins demonstrate a class effect through cholesterol lowering. The model was used to estimate the proportion of patients achieving target LDL‐C levels (